The variety of potentially useful dyes or haptenes available for fluorescent nucleic acid hybridization assays is far greater than what can be obtained from commercial sources 1,2. Since this ...

The increasing incidence of genetic and rare diseases is a major factor driving revenue growth in the Antisense ...

Advancements in manufacturing technologies is a key driver driving nucleic acid therapeutics CDMO market revenue growth.

The global demand for digital data is projected to be greater than the supply of semiconductor grade silicon in 2040 [1]. When combined with the need to archive information [2], nucleic acids are ...